XNASCNTX
Market cap75mUSD
Jan 17, Last price
1.01USD
1D
3.23%
1Q
-50.49%
IPO
-83.63%
Name
Context Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L+67.69%
CFO
-21m
L+55.34%
Profile
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
IPO date
Oct 20, 2021
Employees
9
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 25,085 | 14,890 | |||
Unusual Expense (Income) | |||||
NOPBT | (25,085) | (14,890) | |||
NOPBT Margin | |||||
Operating Taxes | (545) | ||||
Tax Rate | |||||
NOPAT | (25,085) | (14,345) | |||
Net income | (23,964) 67.69% | (14,291) 92.25% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 309 | ||||
BB yield | |||||
| Debt | |||||
Debt current | 55 | ||||
Long-term debt | 55 | ||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (14,450) | (35,387) | |||
| Cash flow | |||||
Cash from operating activities | (21,048) | (13,549) | |||
CAPEX | (537) | ||||
Cash from investing activities | (537) | ||||
Cash from financing activities | (102) | ||||
FCF | (25,021) | (14,425) | |||
| Balance | |||||
Cash | 14,450 | 35,497 | |||
Long term investments | |||||
Excess cash | 14,450 | 35,497 | |||
Stockholders' equity | (68,039) | (44,074) | |||
Invested Capital | 79,910 | 78,888 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 15,966 | 15,966 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (25,073) | (14,881) | |||
EV/EBITDA | |||||
Interest | 547 | ||||
Interest/NOPBT | |||||